Related Experiment Videos

Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity

H Itoh1, Y Hattori, H Sakamoto

  • 1Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Cancer Research
|June 15, 1994
PubMed

Insights

K-SAM, a fibroblast growth factor receptor 2/BEK, is amplified in stomach cancer. A truncated K-SAM variant, prevalent in cancer cells, exhibits higher transforming activity due to alternative splicing.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • K-SAM (fibroblast growth factor receptor 2/BEK) is identified in KATO-III stomach cancer cells.
  • Gene amplification and overexpression of K-SAM are observed in poorly differentiated stomach cancers.

Purpose of the Study:

  • To investigate the role of K-SAM in stomach cancer development.
  • To characterize the K-SAM transcript variants and their functional significance.

Main Methods:

  • Cloning of K-SAM from KATO-III cells.
  • Analysis of K-SAM transcript variants using complementary DNA (cDNA).
  • Assessment of transforming activity in NIH3T3 cells.

Main Results:

  • A major K-SAM transcript in KATO-III cells encodes a truncated receptor with high affinity for keratinocyte growth factor.
  • This truncated variant is produced via alternative splicing and is less common in normal tissues.
  • The variant complementary DNA (cDNA) lacks tyrosine 769, a phospholipase C gamma 1 association site.
  • The truncated K-SAM variant demonstrates higher transforming activity compared to the untruncated form.

Conclusions:

  • Alternative splicing generates a truncated K-SAM variant with increased transforming potential in stomach cancer.
  • This truncated K-SAM may play a significant role in the pathogenesis of poorly differentiated stomach cancers.

Related Concept Videos